Your browser doesn't support javascript.
loading
Scalable efficient expansion of mesenchymal stem cells in xeno free media using commercially available reagents.
Riordan, Neil H; Madrigal, Marialaura; Reneau, Jason; de Cupeiro, Kathya; Jiménez, Natalia; Ruiz, Sergio; Sanchez, Nelsy; Ichim, Thomas E; Silva, Francisco; Patel, Amit N.
Afiliación
  • Riordan NH; Medistem Panama, Inc., Building 221, City of Knowledge, Clayton, Panama City, Republic of Panama. nhriordan@gmail.com.
  • Madrigal M; Medistem Panama, Inc., Building 221, City of Knowledge, Clayton, Panama City, Republic of Panama. marialauramadrigal@medistemresearch.com.
  • Reneau J; Indicasat AIP Panama, City of Knowledge, Rep. of Panama. marialauramadrigal@medistemresearch.com.
  • de Cupeiro K; Acharya Nagarjuna University, Guntur, India. marialauramadrigal@medistemresearch.com.
  • Jiménez N; Amniotic Therapies, LLC, Farmers Branch, TX, USA. jasonreneau@testvalleyresearch.com.
  • Ruiz S; Medistem Panama, Inc., Building 221, City of Knowledge, Clayton, Panama City, Republic of Panama. dekupeirok@medistemresearch.com.
  • Sanchez N; Medistem Panama, Inc., Building 221, City of Knowledge, Clayton, Panama City, Republic of Panama. njimenez@medistemresearch.com.
  • Ichim TE; Medistem Panama, Inc., Building 221, City of Knowledge, Clayton, Panama City, Republic of Panama. sruiz@medistemresearch.com.
  • Silva F; Medistem Panama, Inc., Building 221, City of Knowledge, Clayton, Panama City, Republic of Panama. nsanchez@medistemresearch.com.
  • Patel AN; Coma Research Institute, La Jolla, CA, USA. thomas.ichim@gmail.com.
J Transl Med ; 13: 232, 2015 Jul 17.
Article en En | MEDLINE | ID: mdl-26183703
BACKGROUND: The rapid clinical translation of mesenchymal stem cells (MSC) has resulted in the development of cell-based strategies for multiple indications. Unfortunately one major barrier to widespread implementation of MSC-based therapies is the limited supply of fetal calf serum (FCS) used to expand cells to therapeutic numbers. Additionally, the xenogeneic element of fetal calf serum has been previously demonstrated to stimulate antibody mediated reactions and in some cases sensitization leading to anaphylaxis. METHOD: XcytePLUS™ media, a human platelet lysate based product, was used to supplement the culture medium at 5, 7.5 and 10% and compared to fetal calf serum at 10%, for human umbilical cord MSC expansion. Properties of the expanded cells were investigated. RESULTS: This study demonstrated equivalent or superior effects of human platelet lysate compared to standard FCS supplemented media, based on doubling rate, without loss of identity or function, as demonstrated with flow cytometry characterization. Differentiation into osteocytes, adipocytes and chondrocytes was comparable from cells expanded in either media supplement. CONCLUSIONS: These data support the implementation of human platelet lysate supplemented media as an alternative to xenogeneic containing preparations which may lead to safer MSC products with therapeutic uses.
Asunto(s)

Texto completo: 1 Colección: 01-internacional Asunto principal: Técnicas de Cultivo de Célula / Células Madre Mesenquimatosas Límite: Humans Idioma: En Revista: J transl med Año: 2015 Tipo del documento: Article País de afiliación: Panamá

Texto completo: 1 Colección: 01-internacional Asunto principal: Técnicas de Cultivo de Célula / Células Madre Mesenquimatosas Límite: Humans Idioma: En Revista: J transl med Año: 2015 Tipo del documento: Article País de afiliación: Panamá